Latest News for: cd38

Edit

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

The Joplin Globe 10 Mar 2025
COPENHAGEN, Denmark--(BUSINESS WIRE)--Mar 10, 2025-- ... .
Edit

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 (Genmab A/S)

Public Technologies 10 Mar 2025
2025-03-10 15.13.07 CET Genmab A/S - Inside information Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 ... HexaBody-CD38 (GEN3014) ... 39%, 70%) in the HexaBoby-CD38 IV arm vs.
Edit

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 (Form 6-K) (Genmab A/S)

Public Technologies 10 Mar 2025
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 ... HexaBody-CD38. ● Genmab will not pursue further clinical development of HexaBody-CD38 ... 39%, 70%) in the HexaBoby-CD38 IV arm vs.
Edit

2025 Anti-CD38 Antibody Pipeline Insights for 10+ Companies and 12+ Pipeline Drugs, Including Felzartamab (I-MAB ...

Nasdaq Globe Newswire 04 Mar 2025
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Anti-CD38 Antibody - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering ... Anti-CD38 Antibody Emerging Drugs Chapters ... Anti-CD38 Antibody Emerging Drugs .
  • 1
×